Welcome to our dedicated page for Sinovac Biotech SEC filings (Ticker: SVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sinovac Biotech Ltd. (SVA) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a foreign private issuer listed on Nasdaq. Sinovac furnishes information to the U.S. Securities and Exchange Commission (SEC) primarily through Form 20‑F annual reports and Form 6‑K current reports, which include press releases, proxy materials, and other significant updates.
For a vaccine-focused biopharmaceutical company like Sinovac, annual reports on Form 20‑F and related filings are central sources for understanding its vaccine portfolio, risk factors, and financial condition. While the specific contents of Sinovac’s 20‑F filings are not reproduced here, the company has publicly discussed delays in filing its 2024 annual report and its engagement of independent auditors to complete multi-year audits and internal control assessments. These filings are directly relevant for investors tracking compliance with Nasdaq Listing Rules and SEC reporting requirements.
Sinovac’s Form 6‑K submissions frequently attach press releases covering topics such as special shareholder meetings, litigation outcomes in Antigua and other jurisdictions, proxy advisory recommendations, dividend payments, and board communications. For example, recent 6‑Ks have furnished press releases on the adjournment of a Special Meeting of Shareholders, court decisions related to PIPE shares, the status of a US$55.00 per common share special cash dividend, and the engagement of new independent auditors.
Through this page, users can review Sinovac’s historical and recent 6‑K filings to follow governance disputes, corporate actions, and listing status updates, alongside financial reporting milestones. Stock Titan’s interface is designed to surface new filings as they are made available from EDGAR and to pair them with AI-powered summaries that explain the purpose of each document in plain language, such as distinguishing between a current report on Form 6‑K and an annual report on Form 20‑F.
Investors researching Sinovac’s regulatory history can use this filings archive to examine how the company has communicated about auditor changes, Nasdaq notifications regarding late filings and delisting determinations, proxy contests, and dividend distributions, all of which are documented in its SEC submissions.
Sinovac Biotech Ltd. filed a 6-K describing an Antigua High Court interim order that confirms the current group of eight directors, led by Chairman Andrew Y. Yan, will serve as the Company’s Board until a trial on a disputed July 2025 special shareholder meeting, scheduled for late April/early May 2026.
The Board reiterates its focus on shareholder value, completing the audit, supporting the CEO and management team, and working with advisors to resolve ongoing disputes. It also highlights efforts to restore trading of Sinovac’s shares on NASDAQ and maintain stable operations while advancing its vaccine portfolio and global partnerships.
Sinovac Biotech’s major shareholder SAIF Partners IV and its affiliated entities report continued beneficial ownership of 10,780,820 common shares, representing 15% of the company’s common shares, based on 71,860,702 shares outstanding as of March 31, 2024.
On December 15, 2025, SAIF Partners IV L.P. (the Seller) and YZ Healthcare L.P. (the Buyer) entered into an Amended and Restated Investment Agreement. The revisions extend the Buyer’s right of first refusal period for secondary sales by SAIF and limit the shares covered by that right to an amount equal in value to the Buyer’s deposit under the prior agreement. The amendment also extends the time during which SAIF may exercise a put option to sell designated shares to the Buyer, tied to whether a share purchase agreement is signed before the new right of first refusal period expires.
Sinovac Biotech Ltd. reports that Nasdaq has notified the company it is not in compliance with Listing Rule 5250(c)(2) because it failed to timely file a Form 6-K with interim financial statements for the second quarter of 2025.
Sinovac previously received a Nasdaq staff delisting determination in November 2025 and has appealed. A Nasdaq Hearings Panel will consider both the earlier delisting determination and this new late-filing issue at a hearing scheduled for January 8, 2026, where Sinovac plans to present a plan aimed at maintaining its Nasdaq listing.
Schedule 13D/A Amendment No. 6 filed by Dr. Weidong Yin discloses continued beneficial ownership of 6,359,500 Sinovac Biotech (SVA) common shares, representing 8.85 % of the 71.86 million shares outstanding as reported in the company’s 2023 Form 20-F.
The amendment adds one material update: on 10 July 2025 Sinovac announced a newly constituted 10-member Board of Directors that now includes Dr. Yin. He has accepted the appointment and intends to participate in the issuer’s future governance. Aside from this governance change, Dr. Yin states he currently has no specific plans that would trigger any of clauses (a)–(j) of Item 4 (e.g., mergers, asset sales, recapitalisations). He continues conversations with other shareholders on governance and value-enhancing matters but expressly disclaims acting as a group.
- Ownership structure: Sole voting and dispositive power over the entire 6.36 million-share position; no shared power disclosed.
- Funding source: Personal funds (“PF”).
- Citizenship: China.
No new contracts or arrangements regarding the securities are reported beyond those described in Item 4. The filing is signed by Dr. Yin on 14 July 2025.
Vivo Capital VIII, LLC and Vivo Capital IX, LLC filed Amendment No. 6 to their Schedule 13D regarding Sinovac Biotech Ltd. (NASDAQ: SVA) on 11 July 2025. The filing updates share ownership and details an ongoing proxy and litigation battle over control of Sinovac’s board.
Ownership: Vivo Capital VIII reports 1,361,236 common shares (1.9%); Vivo Capital IX reports 4,541,764 common shares (6.3%), based on 71,860,702 shares outstanding, for a combined 8.2% economic interest. Both entities have shared voting and dispositive power over their respective holdings.
Purpose of transaction: The amendment narrates events surrounding a Special Meeting called for 8 July 2025. Sinovac sought a court injunction to exclude Vivo and another investor from voting. Vivo opposed the injunction; the Eastern Caribbean Court of Appeal stayed enforcement on 8 July, enabling Vivo to vote its shares by proxy in favor of SAIF’s director slate (including Mr. Shan Fu). Sinovac disclosed on 10 July 2025 that the SAIF-backed slate was elected and Mr. Fu joined the board.
Vivo states it will continue to engage with other shareholders and pursue actions under Item 4 of Schedule 13D, such as influencing board composition, dividend policy, auditor replacement, SEC filing compliance, and a potential NASDAQ relisting. Vivo also references multiple legal proceedings, including a 30 June 2025 U.S. District Court injunction compelling disclosure from shareholders linked to Sinovac’s chairman.
Exhibits: Two press releases (2 July 2025 and 9 July 2025) describing the legal developments are incorporated by reference.
Implications for investors: The filing confirms an activist position totaling 8.2% of Sinovac’s equity and outlines continuing efforts to reshape governance. While successful in electing a new board slate, persistent litigation indicates ongoing uncertainty around corporate control and future strategic direction.